
Crystec Limited (CrystecPharma)
Transforming the performance of medicines through advanced particle engineering
Crystec Limited (CrystecPharma) is a pharmaceutical technology company that offers its mSAS® supercritical-fluid particle engineering platform to improve the bioavailability, stability and delivery of small and large molecule therapeutics. Its work is aimed at clients developing new and existing medicines. Headquartered in Bradford, United Kingdom.
Modalities
Development & manufacturing
Structured CDMO capabilities from verified public sources.
Development (D)
Services
Indications
About this organization
Overview
CrystecPharma describes itself as a global pharmaceutical technology company focused on transforming the performance of medicines. Its proprietary mSAS® (modified Supercritical Anti-Solvent) particle engineering platform is presented as a way to optimise new and existing small and large molecule therapeutics.
Technology and applications
The website describes mSAS® as a single-step process for engineering particles to improve:
- Dissolution and solubility of poorly soluble drugs, including increasing surface area, reducing agglomeration, and producing new solid-state forms, co-crystals or stabilised amorphous forms.
- Inhaled therapies, with particle size and shape designed for aerosolisation.
- Chemical and physical stability, including residue-free particles that resist moisture and higher temperatures.
- Formulation simplification, by producing particles that combine the components needed for a medicine to perform.
- Biomolecule processing, including peptides, proteins, antibodies and oligonucleotides, as free-flowing powders.
- Natural product simplification and fine tuning of medicine components.
Sustainability
The site states that, on average, the mSAS® process uses 27% less solvent than micronisation and 80% less than spray drying, with an average 95% yield and improved energy efficiency relative to spray drying and micronisation.
Clients and partners
The website refers to "large and smaller clients" and lists scientific centres in Bradford (UK, headquarters), Tianjin (China), Hangzhou (China, Inhalatec) and Lugano (Switzerland, Inhalis). It also describes Prevista AI, a tool that assesses compound compatibility with the mSAS® technology.
Locations
Bradford (Headquarters)
Bradford · United Kingdom
Tianjin
Tianjin · China
Hangzhou (Inhalatec)
Hangzhou · China
Lugano (Inhalis)
Lugano · Switzerland
Similar companies
Similar profiles by shared services, modalities, and capabilities.
PharmaBlock- Solid-State Chemistry & Polymorph Screening
- Process Development
Lupin Limited- Inhalation & Nasal Dosage Manufacturing
- Process Development
CordenPharma- Solid-State Chemistry & Polymorph Screening
- Inhalation & Nasal Dosage Manufacturing
Porton- Solid-State Chemistry & Polymorph Screening
- Process Development
Gannet Biochem- Process Development
- Formulation Development
Veranova- Solid-State Chemistry & Polymorph Screening
- Process Development
AustinPx- Solid-State Chemistry & Polymorph Screening
- Process Development
Sinopep-Allsino Biopharmaceutical Co., Ltd.- Process Development
- Formulation Development
View all alternatives →See similar CDMOs ranked by shared capabilities
Submit a verified review for this organization.
Markdown mirror: /companies/crystecpharma.md